| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| lnc-HUR1 | Hepatitis B virus (HBV) | MOI: NA ;
MOI: NA |
HepG2-4D14 Human hepatoma cells | qPCR | 2 | Upregulation | p < 0.05 | Comparative threshold cycle (CT) method | student’s t-test | 2018 | 29790592 |
| OIP5-AS1 | Coxsackie virus B3 (CG strain of CVB3) | MOI = 0.5 ;
23 hr |
HeLa Human papillomavirus-related endocervical adenocarcinoma cells | Microarray | 2.2643938 | Upregulation | 1.28E-06 | GeneSpring GX v11.5.1 software package (Agilent Technologies) | student's t test | 2019 | 31388922 |
| OIP5-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 0.568621281 | Downregulation | 2.74E-05 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose